Latest Content

A new multiplex blood-screening assay is streamlining transfusion safety by enabling simultaneous detection and discrimination of HIV, HBV, HCV, and hepatitis E in a single test, helping laboratories improve efficiency, reduce turnaround times, and strengthen blood supply resilience amid ongoing donation and staffing shortages. Nico Michel, PhD, of Roche Diagnostics, offers insights on this diagnostic.

A once-weekly oral HIV treatment combining islatravir and lenacapavir achieved its primary efficacy endpoint in 2 phase 3 trials, bringing the investigational regimen closer to becoming the first approved long-acting oral HIV therapy.

A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.

The FDA's accelerated approval of this therapy provides the first approved treatment option for chronic hepatitis delta in the US. Anu Osinusi, MD, discusses how this targeted therapy is designed to slow disease progression and improve patient outcomes.

American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, discusses how they are reorganizing its structure to create more focused scientific divisions while maintaining collaboration across disciplines and improving member engagement.

Kelly Oakeson, PhD, explains how Utah public health officials are leveraging a statewide wastewater surveillance system to monitor measles activity, identify emerging outbreaks, and supplement traditional case reporting.

New data on flu vaccine for children counter the contention that a lack of contemporaneous randomized data justifies its removal from recommended annual immunizations.

Why people with HIV age faster: Kristine Erlandson, MD, offers expert tips on frailty, HAND screening, statins post-REPRIEVE, and avoiding ART drug interactions.

An increase in Plasmodium vivax malaria in New York City follows trends in migration from regions where it is endemic.

PolyPid has completed its New Drug Application submission to the FDA for D-PLEX100, a novel locally administered antibiotic therapy that significantly reduced surgical site infections in a phase 3 trial and could receive a regulatory decision in early 2027.

The FDA has approved ensitrelvir (Xocova) for postexposure prophylaxis of COVID-19 in adults and children 12 years or older, making it the first and only oral antiviral authorized to help prevent symptomatic infection after exposure.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.

Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.